Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

Aug 06, 2018

|

NEW YORK (GenomeWeb) – Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation's planned blood-based tumor mutational burden test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

To read the full story....

Breaking News

FDA Grants Emergency Use Authorization for George Washington University Coronavirus PCR Test

Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Castle Biosciences Q2 Revenues Up 18 Percent

HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

BioMérieux, Beijing Wantai Coronavirus Antibody Tests Get FDA Emergency Use Authorization

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

What's Popular?

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

International Group Developing Point-of-Care Flow Cytometer for One-Day Diagnosis of Breast Cancer

Paige, Diatron Receive FDA Clearances in July

Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

Sponsorships